JP2023110094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023110094A5 JP2023110094A5 JP2023096315A JP2023096315A JP2023110094A5 JP 2023110094 A5 JP2023110094 A5 JP 2023110094A5 JP 2023096315 A JP2023096315 A JP 2023096315A JP 2023096315 A JP2023096315 A JP 2023096315A JP 2023110094 A5 JP2023110094 A5 JP 2023110094A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- lymphoma
- leukemia
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 230000004850 protein–protein interaction Effects 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111017A JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635834P | 2018-02-27 | 2018-02-27 | |
| US62/635,834 | 2018-02-27 | ||
| JP2020544852A JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| PCT/US2019/019856 WO2019169001A1 (en) | 2018-02-27 | 2019-02-27 | Chromene derivatives as inhibitors of tcr-nck interaction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Division JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111017A Division JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023110094A JP2023110094A (ja) | 2023-08-08 |
| JP2023110094A5 true JP2023110094A5 (https=) | 2023-09-11 |
| JP7521070B2 JP7521070B2 (ja) | 2024-07-23 |
Family
ID=65724589
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Active JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2023096315A Active JP7521070B2 (ja) | 2018-02-27 | 2023-06-12 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2024111017A Pending JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Active JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111017A Pending JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10696663B2 (https=) |
| EP (1) | EP3759086A1 (https=) |
| JP (3) | JP7317032B2 (https=) |
| KR (2) | KR20260028873A (https=) |
| CN (2) | CN112189009B (https=) |
| AU (2) | AU2019229258B2 (https=) |
| BR (1) | BR112020017386A2 (https=) |
| CA (1) | CA3091202A1 (https=) |
| CO (1) | CO2020010537A2 (https=) |
| EA (1) | EA202091742A1 (https=) |
| IL (2) | IL301120B2 (https=) |
| MX (2) | MX2020008814A (https=) |
| PH (1) | PH12020500638A1 (https=) |
| SG (1) | SG11202008067QA (https=) |
| WO (1) | WO2019169001A1 (https=) |
| ZA (1) | ZA202310843B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3759086A1 (en) | 2018-02-27 | 2021-01-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
| WO2025137442A1 (en) * | 2023-12-22 | 2025-06-26 | Artax Biopharma Inc. | SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF |
| WO2025255109A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a pde4 inhibitor |
| WO2025255093A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a car-t therapy and a chromene derivative tcr inhibitor |
| WO2025255091A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a jak inhibitor |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| FR2772761B1 (fr) * | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
| ATE260269T1 (de) | 1999-11-05 | 2004-03-15 | Cytovia Inc | Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| AU2001278980A1 (en) | 2000-07-21 | 2002-02-05 | Chugai Seiyaku Kabushiki Kaisha | Coumarin derivatives useful as tnfalpha inhibitors |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| WO2002092076A1 (en) | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| PL374215A1 (en) * | 2001-08-11 | 2005-10-03 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| WO2003062272A1 (es) | 2002-01-24 | 2003-07-31 | Consejo Superior De Investigaciones Científicas | Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck. |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP1513515A2 (en) | 2002-05-16 | 2005-03-16 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| JP5569857B2 (ja) * | 2007-08-10 | 2014-08-13 | アステラス製薬株式会社 | 二環式アシルグアニジン誘導体 |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2331451B1 (es) | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| EP2326634B1 (en) | 2008-07-16 | 2014-11-05 | Bristol-Myers Squibb Company | Chromene modulators of chemokine receptor activity |
| ES2334318B2 (es) | 2008-09-05 | 2011-11-28 | Universidad Politécnica de Madrid | Sistema de deteccion optica para bio-ensayos de alta sensibilidad sinmarcado. |
| MX2011005954A (es) | 2008-12-05 | 2011-10-11 | Astellas Pharma Inc | Compuesto de 2h-cromeno y su derivado. |
| ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
| US20140171445A1 (en) * | 2011-08-04 | 2014-06-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance |
| EP2693164A1 (en) | 2012-08-03 | 2014-02-05 | Universidad Politécnica de Madrid | Interferometric detection method |
| ES2534318B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| ES2534336B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
| US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| CN104844471B (zh) * | 2015-04-21 | 2017-05-03 | 苏州远智医药科技有限公司 | 一种作为dor受体拮抗剂的化合物 |
| EP3759086A1 (en) | 2018-02-27 | 2021-01-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
-
2019
- 2019-02-27 EP EP19710272.6A patent/EP3759086A1/en active Pending
- 2019-02-27 EA EA202091742A patent/EA202091742A1/ru unknown
- 2019-02-27 AU AU2019229258A patent/AU2019229258B2/en active Active
- 2019-02-27 CN CN201980020981.7A patent/CN112189009B/zh active Active
- 2019-02-27 WO PCT/US2019/019856 patent/WO2019169001A1/en not_active Ceased
- 2019-02-27 MX MX2020008814A patent/MX2020008814A/es unknown
- 2019-02-27 IL IL301120A patent/IL301120B2/en unknown
- 2019-02-27 CA CA3091202A patent/CA3091202A1/en active Pending
- 2019-02-27 KR KR1020267003633A patent/KR20260028873A/ko active Pending
- 2019-02-27 JP JP2020544852A patent/JP7317032B2/ja active Active
- 2019-02-27 BR BR112020017386-0A patent/BR112020017386A2/pt unknown
- 2019-02-27 US US16/287,771 patent/US10696663B2/en active Active
- 2019-02-27 CN CN202311248809.1A patent/CN117304157A/zh active Pending
- 2019-02-27 SG SG11202008067QA patent/SG11202008067QA/en unknown
- 2019-02-27 KR KR1020207027883A patent/KR102924679B1/ko active Active
-
2020
- 2020-05-20 US US16/878,842 patent/US11008310B2/en active Active
- 2020-08-20 PH PH12020500638A patent/PH12020500638A1/en unknown
- 2020-08-24 IL IL276887A patent/IL276887B2/en unknown
- 2020-08-24 MX MX2023005716A patent/MX2023005716A/es unknown
- 2020-08-26 CO CONC2020/0010537A patent/CO2020010537A2/es unknown
-
2021
- 2021-04-26 US US17/240,041 patent/US11807633B2/en active Active
-
2023
- 2023-06-12 JP JP2023096315A patent/JP7521070B2/ja active Active
- 2023-09-21 US US18/471,594 patent/US12319675B2/en active Active
- 2023-11-24 ZA ZA2023/10843A patent/ZA202310843B/en unknown
- 2023-12-12 AU AU2023282201A patent/AU2023282201B2/en active Active
-
2024
- 2024-07-10 JP JP2024111017A patent/JP2024138421A/ja active Pending
-
2025
- 2025-05-01 US US19/196,040 patent/US20250346586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023110094A5 (https=) | ||
| JP2021514007A5 (https=) | ||
| Scherman et al. | Olefin metathesis and quadruple hydrogen bonding: A powerful combination in multistep supramolecular synthesis | |
| IL276887B2 (en) | Novel chromium as inhibitors of tcr–nck interaction | |
| Petro et al. | Microwave Absorption and Molecular Structure in Liquids. XX. Dielectric Relaxation Times and Molecular Shapes of Some Substituted Benzenes and Pyridines1-3 | |
| JP2005515258A5 (https=) | ||
| JP2020537671A5 (https=) | ||
| Mahapatra et al. | Anhydrous adenine: crystallization, structure, and correlation with other nucleobases | |
| Jia et al. | Insights into intermolecular interactions of spironolactone solvates | |
| DE68918877T2 (de) | Verfahren zur Herstellung von cyclischen Polydiorganosiloxanen durch Equilibrierung in der Gasphase. | |
| KR930023364A (ko) | 비페닐메틸-치환 피리돈 | |
| Koizumi et al. | Crystallization technique of high-quality protein crystals controlling surface free energy | |
| JPH0610194B2 (ja) | ビオロゲン誘導体及びその製造方法 | |
| Fouda et al. | Discovery, synthesis, and in vitro characterization of 2, 3 derivatives of 4, 5, 6, 7-tetrahydro-benzothiophene as potent modulators of retinoic acid receptor-related orphan receptor γt | |
| PT1881972E (pt) | Processo para a produção de carbonato de vinileno | |
| Xu et al. | Stepwise Conversion of a Platinum Dimethyl Complex to a Perfluorometallacyclobutane Derivative | |
| JPH05214078A (ja) | プロペランを含むコポリマー及びそれより製造されるコンタクトレンズ | |
| Zhang et al. | Determination and Correlation of Solubilities of 1, 3, 5-Trifluoro-2, 4, 6-triiodobenzene in Different Solvents from 289.25 to 332.15 K | |
| Syrovaya et al. | Investigation of quantum-chemical properties of meloxicam | |
| Chang et al. | Crystal and molecular structure of bis (pyridine-2-carboxamido) nickel (II) dihydrate | |
| Matsumoto et al. | Synthesis of Iodinated Thiazolo [2, 3-a] isoquinolinium salts and their Crystal Structures with/without Halogen Bond | |
| JPH024722A (ja) | 弗素含有環状オレフィン化合物及びその製法 | |
| Hoelm et al. | Study of a new fluorinated compound: variable‐temperature crystallography, thermal expansion, theoretical calculations and biological assays | |
| Capek et al. | On acrylonitrile polymerization in the presence of zinc salts | |
| Prest | Surface modification and controlled assembly of molecular materials |